Latest revenue
$6.96B
as of 2026-03-31
Latest net income
$2.02B
as of 2026-03-31
Net margin
29.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $166.82B
- Enterprise value
- $166.82B
- P/E (trailing)
- 19.6×
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 2.4%
- 52-wk high
- $157.29
- 52-wk low
- $104.46
- Beta
- —
- Shares out
- 1.24B
5-year trend
What this company does
ITEM 1. BUSINESS Gilead Sciences, Inc. (including its consolidated subsidiaries, referred to as “Gilead,” the “company,” “we,” “our” or “us”) is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. We are committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19 and cancer. We operate in more than 35 countries worldwide, with headquarters in Foster City, California. Our Business Products We have transformed care for people around the world by discovering, developing and delivering innovative…
AI summary unavailable — showing raw filing excerpt
Generated from GILD's filing dated 2026-02-24
Key risks
ITEM 1A. RISK FACTORS In evaluating our business, you should carefully consider the following discussion of material risks, events and uncertainties that make an investment in us speculative or risky in addition to the other information in this Annual Report on Form 10-K. A manifestation of any of the following risks and uncertainties could, in circumstances we may or may not be able to accurately predict, materially and adversely affect our business and operations, growth, reputation (including the commercial or scientific reputation of our products), prospects, product pipeline and sales, operating and financial results, financial condition, cash flows, liquidity and stock price. We note…
AI summary unavailable — showing raw filing excerpt
Generated from GILD's filing dated 2026-02-24
Profitability
Operating margin
34.0%
488.9%Net margin
28.9%
1631.4%Return on equity
37.5%
1409.5%Return on assets
14.4%
1672.1%Leverage
Debt / equity
1.60×
22.0%Long-term debt / equity
0.97×
24.3%Debt / assets
61.5%
8.5%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $6.96B | +4.4% | $2.02B | +53.7% | 29.0% |
Q4 2025 2025-12-31 | $7.92B | +4.7% | $2.18B | +22.4% | 27.5% |
Q3 2025 2025-09-30 | $7.77B | +3.0% | $3.05B | +143.6% | 39.3% |
Q2 2025 2025-06-30 | $7.08B | +1.8% | $1.96B | +21.4% | 27.7% |
Q1 2025 2025-03-31 | $6.67B | -0.3% | $1.31B | +131.5% | 19.7% |
Q4 2024 2024-12-31 | $7.57B | — | $1.78B | — | 23.6% |
Q3 2024 2024-09-30 | $7.54B | +7.0% | $1.25B | -42.5% | 16.6% |
Q2 2024 2024-06-30 | $6.95B | +5.4% | $1.61B | +54.4% | 23.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on GILD — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.0M
Insider selling
$78.8M
Net activity
−$76.8M
Distinct insiders
7
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GILD
Institutional value
$39.18B
Total shares held
291.0M
Distinct holders
729
As of
2026-03-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 80.7M | $11.24B | — | New |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 35.1M | $4.90B | — | New |
| 3 | Invesco Ltd. | 15.5M | $2.16B | — | New |
| 4 | Bank of New York Mellon Corp | 15.1M | $2.10B | — | New |
| 5 | Legal & General Group Plc | 10.5M | $1.46B | — | New |
| 6 | DIMENSIONAL FUND ADVISORS LP | 7.7M | $1.08B | — | New |
| 7 | VANGUARD FIDUCIARY TRUST CO | 7.0M | $980.1M | — | New |
| 8 | WELLS FARGO & COMPANY/MN | 6.6M | $923.8M | — | New |
| 9 | DEUTSCHE BANK AG\ | 6.2M | $867.2M | — | New |
| 10 | Boston Partners | 4.3M | $593.1M | — | New |
| 11 | UBS Group AG | 3.9M | $547.8M | — | New |
| 12 | Swiss National Bank | 3.6M | $507.4M | — | New |
| 13 | California Public Employees Retirement System | 3.6M | $499.6M | — | New |
| 14 | TD ASSET MANAGEMENT INC | 3.4M | $470.0M | — | New |
| 15 | Allianz Asset Management GmbH | 3.1M | $431.2M | — | New |
| 16 | Voya Investment Management LLC | 3.1M | $425.5M | — | New |
| 17 | National Pension Service | 3.0M | $421.1M | — | New |
| 18 | Mitsubishi UFJ Asset Management Co., Ltd. | 2.9M | $407.4M | — | New |
| 19 | Vanguard Global Advisers, LLC | 2.8M | $385.8M | — | New |
| 20 | VANGUARD ASSET MANAGEMENT, Ltd | 2.5M | $348.9M | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once GILD's latest filing finishes processing.